Your browser doesn't support javascript.
loading
The impact of inversions across 33,924 families with rare disease from a national genome sequencing project.
Pagnamenta, Alistair T; Yu, Jing; Walker, Susan; Noble, Alexandra J; Lord, Jenny; Dutta, Prasun; Hashim, Mona; Camps, Carme; Green, Hannah; Devaiah, Smrithi; Nashef, Lina; Parr, Jason; Fratter, Carl; Ibnouf Hussein, Rana; Lindsay, Sarah J; Lalloo, Fiona; Banos-Pinero, Benito; Evans, David; Mallin, Lucy; Waite, Adrian; Evans, Julie; Newman, Andrew; Allen, Zoe; Perez-Becerril, Cristina; Ryan, Gavin; Hart, Rachel; Taylor, John; Bedenham, Tina; Clement, Emma; Blair, Ed; Hay, Eleanor; Forzano, Francesca; Higgs, Jenny; Canham, Natalie; Majumdar, Anirban; McEntagart, Meriel; Lahiri, Nayana; Stewart, Helen; Smithson, Sarah; Calpena, Eduardo; Jackson, Adam; Banka, Siddharth; Titheradge, Hannah; McGowan, Ruth; Rankin, Julia; Shaw-Smith, Charles; Evans, D Gareth; Burghel, George J; Smith, Miriam J; Anderson, Emily.
Afiliação
  • Pagnamenta AT; Oxford Biomedical Research Centre, Centre for Human Genetics, University of Oxford, Oxford, UK. Electronic address: alistair@well.ox.ac.uk.
  • Yu J; Oxford Biomedical Research Centre, Centre for Human Genetics, University of Oxford, Oxford, UK; Novo Nordisk Oxford Research Centre, Oxford, UK.
  • Walker S; Genomics England, London, UK.
  • Noble AJ; Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK.
  • Lord J; School of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK; Sheffield Institute for Translational Neuroscience, The University of Sheffield, Sheffield, UK.
  • Dutta P; Oxford Biomedical Research Centre, Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Hashim M; Oxford Biomedical Research Centre, Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Camps C; Oxford Biomedical Research Centre, Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Green H; Oxford Genetics Laboratories, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Devaiah S; Oxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Nashef L; Department of Neurology, King's College Hospital, London, UK.
  • Parr J; Manchester Centre for Genomic Medicine, Manchester University Hospitals NHS Foundation Trust, Health Innovation Manchester, Manchester, UK.
  • Fratter C; Oxford Genetics Laboratories, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Ibnouf Hussein R; Manchester Centre for Genomic Medicine, Manchester University Hospitals NHS Foundation Trust, Health Innovation Manchester, Manchester, UK.
  • Lindsay SJ; Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.
  • Lalloo F; Manchester Centre for Genomic Medicine, Manchester University Hospitals NHS Foundation Trust, Health Innovation Manchester, Manchester, UK.
  • Banos-Pinero B; Oxford Genetics Laboratories, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Evans D; Exeter Genomics Laboratory, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK.
  • Mallin L; Exeter Genomics Laboratory, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK.
  • Waite A; Bristol Genetics Laboratory, North Bristol NHS Trust, Bristol, UK.
  • Evans J; Bristol Genetics Laboratory, North Bristol NHS Trust, Bristol, UK.
  • Newman A; The All Wales Medical Genomics Service, University Hospital of Wales, Cardiff, UK.
  • Allen Z; North Thames Rare and Inherited Disease Laboratory, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
  • Perez-Becerril C; Manchester Centre for Genomic Medicine, Manchester University Hospitals NHS Foundation Trust, Health Innovation Manchester, Manchester, UK.
  • Ryan G; West Midlands Regional Genetics Laboratory, Central and South Genomic Laboratory Hub, Birmingham, UK.
  • Hart R; Liverpool Centre for Genomic Medicine, Liverpool Women's NHS Foundation Trust, Liverpool, UK.
  • Taylor J; Oxford Genetics Laboratories, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Bedenham T; Oxford Genetics Laboratories, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Clement E; North East Thames Regional Genetic Service, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
  • Blair E; Oxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Hay E; North East Thames Regional Genetic Service, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
  • Forzano F; Clinical Genetics Department, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Higgs J; Liverpool Centre for Genomic Medicine, Liverpool Women's NHS Foundation Trust, Liverpool, UK.
  • Canham N; Liverpool Centre for Genomic Medicine, Liverpool Women's NHS Foundation Trust, Liverpool, UK.
  • Majumdar A; Department of Paediatric Neurology, Bristol Children's Hospital, Bristol, UK.
  • McEntagart M; SW Thames Centre for Genomic Medicine, University of London & St George's University Hospitals NHS Foundation Trust, St George's, London, UK.
  • Lahiri N; SW Thames Centre for Genomic Medicine, University of London & St George's University Hospitals NHS Foundation Trust, St George's, London, UK.
  • Stewart H; Oxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Smithson S; Department of Clinical Genetics, University Hospitals Bristol NHS Foundation Trust, Bristol, UK.
  • Calpena E; Clinical Genetics Group, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK; Grupo de Investigación en Biomedicina Molecular, Celular y Genómica, Unidad CIBERER (CB06/07/1030), Instituto de Investigación Sanitaria La Fe (IIS La Fe), Valencia, Spain.
  • Jackson A; Manchester Centre for Genomic Medicine, Manchester University Hospitals NHS Foundation Trust, Health Innovation Manchester, Manchester, UK; Division of Evolution, Infection and Genomics, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
  • Banka S; Manchester Centre for Genomic Medicine, Manchester University Hospitals NHS Foundation Trust, Health Innovation Manchester, Manchester, UK; Division of Evolution, Infection and Genomics, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
  • Titheradge H; Department of Clinical Genetics, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.
  • McGowan R; West of Scotland Centre for Genomic Medicine, Glasgow, UK.
  • Rankin J; Department of Clinical Genetics, Royal Devon University Healthcare NHS Trust, Exeter, UK.
  • Shaw-Smith C; Department of Clinical Genetics, Royal Devon University Healthcare NHS Trust, Exeter, UK.
  • Evans DG; Manchester Centre for Genomic Medicine, Manchester University Hospitals NHS Foundation Trust, Health Innovation Manchester, Manchester, UK; Division of Evolution, Infection and Genomics, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
  • Burghel GJ; Manchester Centre for Genomic Medicine, Manchester University Hospitals NHS Foundation Trust, Health Innovation Manchester, Manchester, UK.
  • Smith MJ; Manchester Centre for Genomic Medicine, Manchester University Hospitals NHS Foundation Trust, Health Innovation Manchester, Manchester, UK.
  • Anderson E; Liverpool Centre for Genomic Medicine, Liverpool Women's NHS Foundation Trust, Liverpool, UK.
Am J Hum Genet ; 111(6): 1140-1164, 2024 Jun 06.
Article em En | MEDLINE | ID: mdl-38776926
ABSTRACT
Detection of structural variants (SVs) is currently biased toward those that alter copy number. The relative contribution of inversions toward genetic disease is unclear. In this study, we analyzed genome sequencing data for 33,924 families with rare disease from the 100,000 Genomes Project. From a database hosting >500 million SVs, we focused on 351 genes where haploinsufficiency is a confirmed disease mechanism and identified 47 ultra-rare rearrangements that included an inversion (24 bp to 36.4 Mb, 20/47 de novo). Validation utilized a number of orthogonal approaches, including retrospective exome analysis. RNA-seq data supported the respective diagnoses for six participants. Phenotypic blending was apparent in four probands. Diagnostic odysseys were a common theme (>50 years for one individual), and targeted analysis for the specific gene had already been performed for 30% of these individuals but with no findings. We provide formal confirmation of a European founder origin for an intragenic MSH2 inversion. For two individuals with complex SVs involving the MECP2 mutational hotspot, ambiguous SV structures were resolved using long-read sequencing, influencing clinical interpretation. A de novo inversion of HOXD11-13 was uncovered in a family with Kantaputra-type mesomelic dysplasia. Lastly, a complex translocation disrupting APC and involving nine rearranged segments confirmed a clinical diagnosis for three family members and resolved a conundrum for a sibling with a single polyp. Overall, inversions play a small but notable role in rare disease, likely explaining the etiology in around 1/750 families across heterogeneous clinical cohorts.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Raras / Inversão Cromossômica Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Am J Hum Genet Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Raras / Inversão Cromossômica Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Am J Hum Genet Ano de publicação: 2024 Tipo de documento: Article